06/04/2026
If you have Primary Biliary Cholangitis (PBC), you've probably heard your doctor talk about "ALP" – a blood marker that measures liver damage. High ALP levels mean your liver is under attack. The goal of treatment is to bring ALP down to normal levels, which is linked to better long-term outcomes and a lower risk of needing a liver transplant.
Now, new data from multiple clinical trials show that the medication Livdelzi (seladelpar) is helping more PBC patients reach that goal – including those with only moderately elevated ALP levels who have been underrepresented in past studies.
In one ongoing study tracking patients for up to two years, 83% achieved normal ALP levels after one year and 74% after two years. Another analysis found that among patients who responded well to Livdelzi in the first year, 85% showed either stabilization or reduction in liver scarring (fibrosis) over three years.
Livdelzi is already approved as an add-on for patients who don't respond fully to the standard medication UDCA, or for those who cannot tolerate UDCA. It also helps relieve itching, one of PBC's most debilitating symptoms.
How this benefits patients: If you're on UDCA but your ALP levels remain above normal, Livdelzi offers a proven second option to protect your liver long-term. These new studies show it works even for people with mild-to-moderate ALP elevations – not just severe cases. Talk to your hepatologist about whether adding Livdelzi could help you reach ALP normalization and reduce your risk of disease progression.
Livdelzi (seladelpar) effectively reduces levels of alkaline phosphatase (ALP), a key marker of liver damage, per data from PBC trials.
